CliffBio
small molecule

JADENU SPRINKLE

DEFERASIROX

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameJADENU SPRINKLE
Active ingredientDEFERASIROX
Strength180MG
Dosage formGRANULE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2017
Marketing statusRX

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.